[{"id":"3a7c0f48-9cde-43fb-9f10-f7d6361a8ad6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04319757","created_at":"2021-01-18T20:55:53.710Z","updated_at":"2024-07-02T16:35:53.790Z","phase":"Phase 1","brief_title":"ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors","source_id_and_acronym":"NCT04319757","lead_sponsor":"Acepodia Biotech, Inc.","biomarkers":" HER-2 • IL6 • IL2 • IL10","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • ACE1702 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/19/2020","start_date":" 05/19/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-03-08"}]